San Francisco Bay Area biotech stories.
Friday, September 28, 2012
Executive Profile: Plexxikon's Kathleen Glaub
Coming from a family of immigrant entrepreneurs, Kathy Glaub
carried on the family tradition by joining drug development company Plexxikon in 2001 as its 10th employee
. She has helped guide the company, now with 45 employees, through one of the most celebrated drug approvals of the past 10 years, the metastatic melanoma drug Zelboraf in August 2011. Along with a commercialization deal with Genentech Inc. and a companion diagnostic by Roche Molecular Diagnostics, Zelboraf set up Plexxikon for its April 2011 sale to Daiichi Sankyo for a potential $935 million.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)